Consistently, MEK inhibitors [21] efficiently decrease tumor growth of mouse xenografts formed by neuroblastoma cell lines possessing a mutation in the RAS-MAPK relevant pathway, implicating a benefit of putting the “brakes” on the aberrant proliferation in patients with neuroblastomas, presumably even with MYCN amplification (Figure 1). The gene discussed is MYCN; the disease is neuroblastoma.